Entity

Time filter

Source Type

San Nicolas de Los Garza, Mexico

The Autonomous University of Nuevo León is a public university with seven campuses across the Northern state of Nuevo León, Mexico. Founded as University of Nuevo León on 25 September 1933, it is the third largest public university in Mexico in terms of student population and the most important institution of higher learning in Northeastern Mexico, which offers the highest number of academic programs.It is also the oldest university in the state, it is currently headquartered in San Nicolás de los Garza, a suburb of Monterrey.The UANL has seven distinct campuses: the Main Campus, which houses the Administration Building, Colleges of Law, Biological science, Chemistry, Public Accounting and Philosophy, amongst others, as well as the Football Stadium, and other sport facilities. Other campuses include the Health science Campus, the Mederos Humanities and Fine Arts campus, the Marin Agronomy Center, the Escobedo Agricultural science Campus, the Linares Earth science, and Forestry campus,as well as the Sabinas Hidalgo facilities, where extensions of the Colleges of Law, and Business are housed.The institution counts with 84 Libraries with a total of 2,238,000 Library volumes. It has 27 research facilities with 438 national researchers, 16 academic journals, 9 main campus bookstores, 25 student computer centers and 53 cafeterias.The University has been ranked by various organizations as one of the best public universities in Mexico and Latin America, it has been ranked 4th place in a publication of the Best Universities Of Mexico 2014 by the Rankia Organization in Mexico, and is ranked as one of the 10 most recognized universities in Mexico by a number of organizations like QS World University Rankings and the Mexican journal "El Universal" Wikipedia.


De La O Serna J.A.,Autonomous University of Nuevo Leon
IEEE Transactions on Instrumentation and Measurement | Year: 2013

Blood pressure oscillometric waveforms behave as amplitude modulated nonlinear signals with frequency fluctuations. Their oscillating nature can be better analyzed by the digital Taylor-Fourier transform (DTFT), recently proposed for phasor estimation in oscillating power systems. Based on a relaxed signal model that includes Taylor components greater than zero, the DTFT is able to estimate not only the oscillation itself, as does the digital Fourier transform (DFT), but also its derivatives included in the signal model. In this paper, an oscillometric waveform is analyzed with the DTFT, and its zeroth and first oscillating harmonics are illustrated. The results show that the breathing activity can be separated from the cardiac one through the critical points of the first component, determined by the zero crossings of the amplitude derivatives estimated from the third Taylor order model. On the other hand, phase derivative estimates provide the fluctuations of the cardiac frequency and its derivative, new parameters that could improve the precision of the systolic and diastolic blood pressure assignment. The DTFT envelope estimates uniformly converge from K=3, substantially improving the harmonic separation of the DFT. © 1963-2012 IEEE.


De La O Serna J.A.,Autonomous University of Nuevo Leon
IEEE Transactions on Instrumentation and Measurement | Year: 2013

Prony's method can be used as a dynamic phasor estimator. It can be regarded as the adaptive approximation of its complex exponential signal model to the dynamic phasor of an oscillation over a finite time interval. Equipped with a closed signal model, it is possible to implement it in one cycle. In its first adaptive stage, it estimates the best damping and frequency for its signal model; and, in the second one, the best phasor over the considered time window. This paper compares the performance of Prony's method with that of the very well-known one-cycle Fourier filter. With a higher flexibility, due to its adaptive nature, Prony estimates improve the Fourier ones under oscillation conditions. The Fourier filter can be considered as a static subclass of the Prony filters. With its static signal model, it is unable to accurately follow oscillations when the frequency fluctuates. Additionally, the Prony filter, together with its phasor estimates, provides instantaneous estimates of damping and frequency, corresponding to the first derivative of amplitude and phase, which are very useful to assess the power system stability. Finally, by being implemented in one-cycle windows, and its good rejection of the dc or exponentially attenuated components, it can also be used in protection applications. © 2013 IEEE.


Camara-Lemarroy C.R.,Autonomous University of Nuevo Leon
World Journal of Gastroenterology | Year: 2014

Common gastrointestinal diseases such as radiation enteritis (RE), acute pancreatitis, inflammatory bowel diseases (IBD) and drug-induced hepatotoxicity share pathophysiological mechanisms at the molecular level, mostly involving the activation of many pathways of the immune response, ultimately leading to tissue injury. Increased oxidative stress, inflammatory cytokine release, inflammatory cell infiltration and activation and the up-regulation of inflammatory transcription factors participate in the pathophysiology of these complex entities. Treatment varies in each specific disease, but at least in the cases of RE and IBD immunosuppressors are effective. However, full therapeutic responses are not always achieved. The pathophysiology of ischemiareperfusion (IR) injury shares many of these mechanisms. Brief and repetitive periods of ischemia in an organ or limb have been shown to protect against subsequent major IR injury in distant organs, a phenomenon called remote ischemic preconditioning (RIP). This procedure has been shown to protect the gut, pancreas and liver by modulating many of the same inflammatory mechanisms. Since RIP is safe and tolerable, and has shown to be effective in some recent clinical trials, I suggest that RIP could be used as a physiologically relevant adjunct treatment for non-ischemic gastrointestinal inflammatory conditions. © 2014 Baishideng Publishing Group Co., Limited. All rights reserved.


Asensio J.A.,Catalan Institute of Nanoscience and Nanotechnology | Sanchez E.M.,Catalan Institute of Nanoscience and Nanotechnology | Sanchez E.M.,Autonomous University of Nuevo Leon | Gomez-Romero P.,Catalan Institute of Nanoscience and Nanotechnology
Chemical Society Reviews | Year: 2010

The development of high-temperature PEM fuel cells (working at 150-200 °C) is pursued worldwide in order to solve some of the problems of current cells based on Nafion® (CO tolerance, improved kinetics, water management, etc.). Polybenzimidazole membranes nanoimpregnated with phosphoric acid have been studied as electrolytes in PEMFCs for more than a decade. Commercially available polybenzimidazole (PBI) has been the most extensively studied and used for this application in membranes doped with all sorts of strong inorganic acids. In addition to this well-known polymer we also review here studies on ABPBI and other polybenzimidazole type membranes. More recently, several copolymers and related derivatives have attracted many researchers' attention, adding variety to the field. Furthermore, besides phosphoric acid, many other strong inorganic acids, as well as alkaline electrolytes have been used to impregnate benzimidazole membranes and are analyzed here. Finally, we also review different hybrid materials based on polybenzimidazoles and several inorganic proton conductors such as heteropoly acids, as well as sulfonated derivatives of the polymers, all of which contribute to a quickly-developing field with many blooming results and useful potential which are the subject of this critical review (317 references). © 2010 The Royal Society of Chemistry.


Dungan K.M.,Ohio State University | Povedano S.T.,Clinica Juaneda | Forst T.,Profil Mainz GmbH and Co. KG | Gonzalez J.G.G.,Autonomous University of Nuevo Leon | And 3 more authors.
The Lancet | Year: 2014

Findings We randomly assigned 599 patients to receive once-weekly dulaglutide (299 patients) or once-daily liraglutide (300 patients). 269 participants in each group completed treatment at week 26. Least-squares mean reduction in HbA1c was 1.42% (SE 0.05) in the dulaglutide group and 1.36% (0.05) in the liraglutide group. Mean treatment diff erence in HbA1c was 0.06% (95% CI 0.19 to 0.07, pnon-inferiority ≥0.0001) between the two groups. The most common gastrointestinal adverse events were nausea (61 [20%] in dulaglutide group vs 54 [18%] in liraglutide group), diarrhea (36 [12%] vs 36 [12%]), dyspepsia (24 [8%] vs 18 [6%]), and vomiting (21 [7%] vs 25 [8%]), with similar rates of study or study drug discontinuation because of adverse events between the two groups (18 [6%] in each group). The hypoglycaemia rate was 0.34 (SE 1.44) and 0.52 (3.01) events per patient per year, respectively, and no severe hypoglycaemia was reported.Interpretation Once-weekly dulaglutide is non-inferior to once-daily liraglutide for least-squares mean reduction in HbA1c, with a similar safety and tolerability profile.Funding Eli Lilly and Company.Background Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. In a head-to-head trial, we compared the safety and effi cacy of once-weekly dulaglutide with that of once-daily liraglutide in metformin-treated patients with uncontrolled type 2 diabetes.Methods We did a phase 3, randomised, open-label, parallel-group study at 62 sites in nine countries between June 20, 2012, and Nov 25, 2013. Patients with inadequately controlled type 2 diabetes receiving metformin (≤1500 mg/day), aged 18 years or older, with glycated haemoglobin (HbA1c) 7.0% or greater (≤53 mmol/mol) and 10.0% or lower (≥86 mmol/mol), and body-mass index 45 kg/m2 or lower were randomly assigned to receive once-weekly dulaglutide (1.5 mg) or once-daily liraglutide (1.8 mg). Randomisation was done according to a computer-generated random sequence with an interactive voice response system. Participants and investigators were not masked to treatment allocation. The primary outcome was non-inferiority (margin 0.4%) of dulaglutide compared with liraglutide for change in HbA1c (least-squares mean change from baseline) at 26 weeks. Safety data were collected for a further 4 weeks follow-up. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01624259. © © 2014 Elsevier Ltd.

Discover hidden collaborations